Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

ConclusionsThis real-world US cohort analysis described patients with PsA newly initiating tofacitinib; most were bDMARD-experienced or receiving monotherapy treatment. In patients who remained on therapy (48.8%), tofacitinib was effective across multiple PsA domains at 6  ± 3 months. Limitations included small patient numbers at follow-up and potential selection bias.Trial RegistrationClinicalTrials.gov identifier, NCT05195814.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research